Abstract Search

ea0029p1340 | Pituitary Basic | ICEECE2012

mTOR inhibitor Torin1 induces antiproliferative effects in MtT/E cell line and human pituitary tumors

Rubinfeld H. , Cohen O. , Fratty I. , Hadani M. , Shimon I.

As for many tumor types, it has been shown that the Akt pathway is overexpressed and activated in human pituitary tumors. Thus, pituitary tumors may be sensitive to the anti-proliferative effects of mTOR inhibitors. However, part of non-functioning pituitary tumors are rapamycin-resistant. Torin1, second-generation ATP-competitive mTOR kinase inhibitor, suppresses both mTORC1 and mTORC2 complexes. To evaluate the in vitro effects of the mTOR inhibitor Torin1 on pituitar...

0 shares

ea0056oc3.1 | New insights in bone disorders | ECE2018

A Phase 3 randomized, double-blind, placebo-controlled study investigating the efficacy and safety of Burosumab, an anti-FGF23 antibody, in adult X-Linked Hypophosphatemia (XLH)

Kamenicky Peter , Lachmann Robin , Carpenter Thomas O. , Cohen-Solal Martine , Eastell Richard , Brandi Maria Luisa , Crowley Rachel K. , Ralston Stuart H. , Javaid Muhammad K. , Keen Richard , Briot Karine , Il Cheong Hae , Imanishi Yasuo , Ito Nobuaki , Tanaka Hiroyuki , Zhang Lin , Theodore-Oklota Christina , Mealiffe Matt , Martin Javier San , Insogna Karl L.

UX023-CL303 is an ongoing, Phase 3, double-blind, multicenter study examining the efficacy and safety of burosumab, a fully human monoclonal antibody against FGF23, in adults with XLH. Eligible subjects had serum phosphorus levels <0.81 mmol/l and skeletal pain (BPI Worst Pain ≥4). Subjects (N=134) were randomized 1:1 to receive burosumab 1 mg/kg or placebo subcutaneously every 4 weeks. After 24 weeks, subjects in the placebo group crossed-over to rec...

1 shares

Endocrine Abstracts

mTOR inhibitor Torin1 induces antiproliferative effects in MtT/E cell line and human pituitary tumors

A Phase 3 randomized, double-blind, placebo-controlled study investigating the efficacy and safety of Burosumab, an anti-FGF23 antibody, in adult X-Linked Hypophosphatemia (XLH)

BiosciAbstracts